GLPwatch
[Pharmacotherapy for obesity].
Ugeskr Laeger · 2016
Last updated 2026-05-28Obesity is treated with medication if diet and exercise alone don’t lead to at least a 5% weight loss. Medications like liraglutide (3 mg) or orlistat (120 mg or 60 mg) may be used for people with a BMI over 30 or over 27 with conditions like Type 2 diabetes. Treatment should stop if weight loss is less than 5% (about 4-5 kg) after 12 weeks.
AI summary of the abstract below.
| Journal | Ugeskr Laeger, 2016 |
|---|---|
| Citations | 0 |
| Relative citation ratio | 0.00 |
| NIH percentile | 0 |
| Molecules | — |
| Conditions studied | Obesity |
Abstract
Obesity is a chronic condition, which is why pharmacotherapy can be considered, if lifestyle modification (hypocaloric diet/exercise) does not result in a weight loss of at least 5%. Pharmacotherapy is indicated, if an individual has a BMI > 30 kg/m or a BMI > 27 kg/m and concomitant disease (e.g. Type 2 diabetes), and can be liraglutide (3 mg) or orlistat (120 mg/60 mg). Choice of treatment must be based on patient preferences and clinical situation, side effects, contraindications and financial considerations. Weight loss of < 5% (about 4-5 kg) after 12 weeks should lead to cessation of the treatment.
Verbatim abstract via PubMed 27808050 ↗